Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP-700 infusion dose optimization study in healthy adults
NL-OMON42498Phase 1Active, not recruiting
- Sponsor
- Annovation Biopharma, Inc. (a wholly owned subsidiary of The Medicines Company)
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of moxetomidate in Not applicable (2 arms), sponsored by Annovation Biopharma, Inc. (a wholly owned subsidiary of The Medicines Company). Primary endpoints: Safety and tolerability and Optimal infusion schema. Started Aug 2015; status: active, not recruiting.
02
Drugs
moxetomidate
03
Conditions
Not applicable
Beyond the preview
Go deeper on NL-OMON42498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42498.